India
· Delayed Price · Currency is INR Jagsonpal Pharmaceuticals Statistics
Total Valuation
NSE:JAGSNPHARM has a market cap or net worth of INR 15.64 billion. The enterprise value is 14.44 billion.
| Market Cap | 15.64B |
| Enterprise Value | 14.44B |
Important Dates
The last earnings date was Monday, May 19, 2025.
| Earnings Date | May 19, 2025 |
| Ex-Dividend Date | Sep 6, 2024 |
Share Statistics
NSE:JAGSNPHARM has 66.53 million shares outstanding. The number of shares has increased by 1.46% in one year.
| Current Share Class | 66.53M |
| Shares Outstanding | 66.53M |
| Shares Change (YoY) | +1.46% |
| Shares Change (QoQ) | -0.47% |
| Owned by Insiders (%) | 13.50% |
| Owned by Institutions (%) | 1.46% |
| Float | 14.49M |
Valuation Ratios
The trailing PE ratio is 28.59.
| PE Ratio | 28.59 |
| Forward PE | n/a |
| PS Ratio | 5.82 |
| PB Ratio | 6.52 |
| P/TBV Ratio | 10.13 |
| P/FCF Ratio | 28.45 |
| P/OCF Ratio | 28.27 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 28.27, with an EV/FCF ratio of 26.28.
| EV / Earnings | 26.08 |
| EV / Sales | 5.37 |
| EV / EBITDA | 28.27 |
| EV / EBIT | 33.63 |
| EV / FCF | 26.28 |
Financial Position
The company has a current ratio of 6.22, with a Debt / Equity ratio of 0.04.
| Current Ratio | 6.22 |
| Quick Ratio | 5.48 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | 0.18 |
| Debt / FCF | 0.17 |
| Interest Coverage | 44.82 |
Financial Efficiency
Return on equity (ROE) is 25.91% and return on invested capital (ROIC) is 12.05%.
| Return on Equity (ROE) | 25.91% |
| Return on Assets (ROA) | 10.84% |
| Return on Invested Capital (ROIC) | 12.05% |
| Return on Capital Employed (ROCE) | 17.02% |
| Revenue Per Employee | 2.62M |
| Profits Per Employee | 540,107 |
| Employee Count | 1,025 |
| Asset Turnover | 1.08 |
| Inventory Turnover | 6.39 |
Taxes
In the past 12 months, NSE:JAGSNPHARM has paid 144.98 million in taxes.
| Income Tax | 144.98M |
| Effective Tax Rate | 20.75% |
Stock Price Statistics
The stock price has increased by +75.87% in the last 52 weeks. The beta is 0.15, so NSE:JAGSNPHARM's price volatility has been lower than the market average.
| Beta (5Y) | 0.15 |
| 52-Week Price Change | +75.87% |
| 50-Day Moving Average | 224.08 |
| 200-Day Moving Average | 219.48 |
| Relative Strength Index (RSI) | 55.29 |
| Average Volume (20 Days) | 186,536 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NSE:JAGSNPHARM had revenue of INR 2.69 billion and earned 553.61 million in profits. Earnings per share was 8.22.
| Revenue | 2.69B |
| Gross Profit | 1.72B |
| Operating Income | 429.40M |
| Pretax Income | 698.59M |
| Net Income | 553.61M |
| EBITDA | 510.71M |
| EBIT | 429.40M |
| Earnings Per Share (EPS) | 8.22 |
Balance Sheet
The company has 1.29 billion in cash and 92.39 million in debt, giving a net cash position of 1.19 billion or 17.96 per share.
| Cash & Cash Equivalents | 1.29B |
| Total Debt | 92.39M |
| Net Cash | 1.19B |
| Net Cash Per Share | 17.96 |
| Equity (Book Value) | 2.40B |
| Book Value Per Share | 35.72 |
| Working Capital | 1.35B |
Cash Flow
In the last 12 months, operating cash flow was 553.00 million and capital expenditures -3.48 million, giving a free cash flow of 549.52 million.
| Operating Cash Flow | 553.00M |
| Capital Expenditures | -3.48M |
| Free Cash Flow | 549.52M |
| FCF Per Share | 8.26 |
Margins
Gross margin is 64.11%, with operating and profit margins of 15.98% and 20.60%.
| Gross Margin | 64.11% |
| Operating Margin | 15.98% |
| Pretax Margin | 26.00% |
| Profit Margin | 20.60% |
| EBITDA Margin | 19.01% |
| EBIT Margin | 15.98% |
| FCF Margin | 20.45% |
Dividends & Yields
This stock pays an annual dividend of 2.50, which amounts to a dividend yield of 1.06%.
| Dividend Per Share | 2.50 |
| Dividend Yield | 1.06% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 23.90% |
| Buyback Yield | -1.46% |
| Shareholder Yield | -0.41% |
| Earnings Yield | 3.54% |
| FCF Yield | 3.51% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on January 8, 2025. It was a forward split with a ratio of 2.5.
| Last Split Date | Jan 8, 2025 |
| Split Type | Forward |
| Split Ratio | 2.5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |